TOI vs USPH vs JPM

For growth investors, The Oncology Institute, Inc.

(TOI) is the stronger pick with 27. 8% revenue growth year-over-year, versus 3. 3% for JPMorgan Chase & Co. (JPM). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 0x trailing P/E (14. 4x forward), making it the more compelling value choice. Analysts rate The Oncology Institute, Inc. (TOI) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, JPMorgan Chase & Co.

(JPM) is the cheapest at 16. 0x versus U. S. Physical Therapy, Inc. at 46. 2x. On forward P/E, JPMorgan Chase & Co. is actually cheaper at 14. 4x.

Over the past 5 years, JPMorgan Chase & Co.

(JPM) delivered a total return of +118. 2%, compared to -47. 4% for The Oncology Institute, Inc. (TOI). Over 10 years, the gap is even starker: JPM returned +465. 8% versus TOI's -45. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), U.

S. Physical Therapy, Inc. (USPH) is the lower-risk stock at 0. 89β versus The Oncology Institute, Inc. 's 1. 95β — meaning TOI is approximately 119% more volatile than USPH relative to the S&P 500. On balance sheet safety, U. S. Physical Therapy, Inc. (USPH) carries a lower debt/equity ratio of 55% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), The Oncology Institute, Inc.

(TOI) is pulling ahead at 27. 8% versus 3. 3% for JPMorgan Chase & Co. (JPM). On earnings-per-share growth, the picture is similar: The Oncology Institute, Inc. grew EPS 23. 9% year-over-year, compared to -22. 8% for U. S. Physical Therapy, Inc.. Over a 3-year CAGR, TOI leads at 25. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

JPMorgan Chase & Co.

(JPM) is the more profitable company, earning 20. 4% net margin versus -12. 1% for The Oncology Institute, Inc. — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus -7. 2% for TOI. At the gross margin level — before operating expenses — JPM leads at 59. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, JPMorgan Chase & Co.

(JPM) trades at 14. 4x forward P/E versus 22. 6x for U. S. Physical Therapy, Inc. — 8. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TOI: 50. 7% to $8. 00.

In this comparison, USPH (2.

8% yield), JPM (1. 9% yield) pay a dividend. TOI does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, JPMorgan Chase & Co.

(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 94), 1. 9% yield, +465. 8% 10Y return). The Oncology Institute, Inc. (TOI) carries a higher beta of 1. 95 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JPM: +465. 8%, TOI: -45. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (TOI (Healthcare) and USPH (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: TOI is a small-cap high-growth stock; USPH is a small-cap high-growth stock; JPM is a large-cap deep-value stock. USPH, JPM pay a dividend while TOI does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.